|
64
|
241
|
5l61G |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
62
|
241
|
5l64G |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
67
|
233
|
5l5qM |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18 |
|
65
|
216
|
5lf1M |
Human 20s proteasome complex with dihydroeponemycin at 2.0 angstrom |
|
60
|
195
|
5l5hJ |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
68
|
233
|
5l5wM |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) |
|
68
|
242
|
5laiD |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
59
|
226
|
5laiH |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
67
|
239
|
5le5F |
Native human 20s proteasome at 1.8 angstrom |
|
59
|
195
|
5l5eJ |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib |
|
62
|
231
|
5lajE |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
69
|
243
|
5l54F |
Yeast 20s proteasome in complex with epoxyketone inhibitor 16 |
|
71
|
244
|
5l5rB |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
62
|
220
|
5lf4H |
Human 20s proteasome complex with delanzomib at 2.0 angstrom |
|
65
|
211
|
5l62K |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
70
|
243
|
5l69F |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
54
|
233
|
5mp9F |
26s proteasome in presence of atp (s1) |
|
62
|
222
|
5l5hL |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
45
|
236
|
5m32F |
Human 26s proteasome in complex with oprozomib |
|
59
|
195
|
5l5iJ |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 |
|
61
|
195
|
5laiJ |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
61
|
220
|
5leyH |
Human 20s proteasome complex with oprozomib at 1.9 angstrom |
|
65
|
211
|
5l5vK |
'yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
66
|
250
|
5l66A |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib |
|
63
|
222
|
5lajL |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
64
|
200
|
5lf0K |
Human 20s proteasome complex with epoxomicin at 2.4 angstrom |
|
69
|
243
|
5lajF |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
70
|
212
|
5bxlK |
Yeast 20s proteasome beta2-g170a mutant |
|
67
|
242
|
5lajD |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
67
|
233
|
5l5jM |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
62
|
222
|
5l61L |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
42
|
196
|
5mp91 |
26s proteasome in presence of atp (s1) |
|
62
|
211
|
5l5zK |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib |
|
65
|
240
|
5l5iC |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 |
|
71
|
243
|
5l5wF |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) |
|
76
|
248
|
5lf6B |
Human 20s proteasome complex with z-lly-ketoaldehyde at 2.1 angstrom |
|
68
|
240
|
5l5uC |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
64
|
233
|
5le5D |
Native human 20s proteasome at 1.8 angstrom |
|
67
|
244
|
5lajB |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
62
|
233
|
5lf0D |
Human 20s proteasome complex with epoxomicin at 2.4 angstrom |
|
69
|
250
|
5l5rA |
Yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) |
|
67
|
250
|
5l65A |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with carfilzomib |
|
64
|
237
|
5lf6C |
Human 20s proteasome complex with z-lly-ketoaldehyde at 2.1 angstrom |
|
65
|
240
|
5lajC |
Ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters |
|
68
|
239
|
5lf3F |
Human 20s proteasome complex with bortezomib at 2.1 angstrom |
|
53
|
229
|
5mp97 |
26s proteasome in presence of atp (s1) |
|
56
|
195
|
5l5yJ |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib |
|
59
|
196
|
5laiN |
Ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters |
|
68
|
242
|
5l5bD |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) |
|
60
|
196
|
5l6aN |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
